Optimi Health Corp. Common Shares

Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.